|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM262908271 |
| 003 |
DE-627 |
| 005 |
20250220113730.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1021/acs.langmuir.6b01715
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0876.xml
|
| 035 |
|
|
|a (DE-627)NLM262908271
|
| 035 |
|
|
|a (NLM)27468799
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Tukappa, Asha
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Polyglutamic Acid-Gated Mesoporous Silica Nanoparticles for Enzyme-Controlled Drug Delivery
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 19.06.2018
|
| 500 |
|
|
|a Date Revised 20.06.2018
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Mesoporous silica nanoparticles (MSNs) are highly attractive as supports in the design of controlled delivery systems that can act as containers for the encapsulation of therapeutic agents, overcoming common issues such as poor water solubility and poor stability of some drugs and also enhancing their bioavailability. In this context, we describe herein the development of polyglutamic acid (PGA)-capped MSNs that can selectively deliver rhodamine B and doxorubicin. PGA-capped MSNs remain closed in an aqueous environment, yet they are able to deliver the cargo in the presence of pronase because of the hydrolysis of the peptide bonds in PGA. The prepared solids released less than 20% of the cargo in 1 day in water, whereas they were able to reach 90% of the maximum release of the entrapped guest in ca. 5 h in the presence of pronase. Studies of the PGA-capped nanoparticles with SK-BR-3 breast cancer cells were also undertaken. Rhodamine-loaded nanoparticles were not toxic, whereas doxorubicin-loaded nanoparticles were able to efficiently kill more than 90% of the cancer cells at a concentration of 100 μg/mL
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antibiotics, Antineoplastic
|2 NLM
|
| 650 |
|
7 |
|a Rhodamines
|2 NLM
|
| 650 |
|
7 |
|a Polyglutamic Acid
|2 NLM
|
| 650 |
|
7 |
|a 25513-46-6
|2 NLM
|
| 650 |
|
7 |
|a Silicon Dioxide
|2 NLM
|
| 650 |
|
7 |
|a 7631-86-9
|2 NLM
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 650 |
|
7 |
|a Pronase
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.24.-
|2 NLM
|
| 650 |
|
7 |
|a rhodamine B
|2 NLM
|
| 650 |
|
7 |
|a K7G5SCF8IL
|2 NLM
|
| 700 |
1 |
|
|a Ultimo, Amelia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a de la Torre, Cristina
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pardo, Teresa
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sancenón, Félix
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Martínez-Máñez, Ramón
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Langmuir : the ACS journal of surfaces and colloids
|d 1985
|g 32(2016), 33 vom: 23. Aug., Seite 8507-15
|w (DE-627)NLM098181009
|x 1520-5827
|7 nnns
|
| 773 |
1 |
8 |
|g volume:32
|g year:2016
|g number:33
|g day:23
|g month:08
|g pages:8507-15
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1021/acs.langmuir.6b01715
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_721
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 32
|j 2016
|e 33
|b 23
|c 08
|h 8507-15
|